Tresiba Cost in Louisiana 2026: Cash Price, Medicaid, and Savings Options

What Is the Actual Cash Price of Tresiba in Louisiana in 2026?

The cash price Louisiana patients pay in 2026 is nowhere near the $510 list price. Discount programs reduce the out-of-pocket cost to approximately $35 per month at most major Louisiana retail chains. That gap between list and street price reflects manufacturer rebates, pharmacy benefit negotiations, and third-party coupon aggregators rather than any change to the drug itself.

Insulin degludec (brand name Tresiba) is a long-acting basal insulin with a half-life of roughly 25 hours, producing a flat, steady pharmacokinetic profile that the FDA reviewed and approved in September 2015 for adults and children aged 1 year and older with type 1 or type 2 diabetes [1]. Its ultra-long action time means once-daily dosing is genuinely flexible, a feature confirmed in the DEVOTE cardiovascular outcomes trial published in the New England Journal of Medicine in 2017 [2].

Pricing at Louisiana pharmacies varies by chain. GoodRx-negotiated prices for one Tresiba FlexTouch pen (3 mL, 100 units/mL) generally fall between $160 and $210 per pen at Walgreens, CVS, Walmart, and Costco Baton Rouge locations. A standard monthly supply is three pens, so the effective monthly cost before any manufacturer coupon is approximately $480 to $630 at list. After applying the Novo Nordisk savings card or a GoodRx coupon, the price drops to the $35 range for commercially insured or cash-pay patients who qualify [3].

Patients should present one discount card at a time. Pharmacies cannot stack a GoodRx coupon on top of the Novo Nordisk savings card in the same transaction.

Does Louisiana Medicaid Cover Tresiba?

Louisiana Medicaid does not cover Tresiba as of the current 2025 Louisiana Medicaid Preferred Drug List [4]. Long-acting insulin alternatives on the Louisiana Medicaid preferred list include insulin glargine (Lantus biosimilars) and insulin detemir (Levemir). Medicaid members who require insulin degludec specifically must obtain a prior authorization, and approvals have historically been limited to documented failure of two preferred alternatives.

The American Diabetes Association 2024 Standards of Care state: "The choice of insulin regimen should be individualized based on patient preferences, hypoglycemia risk, effect on weight, cost, and access." [5] That guideline language directly supports a prior authorization argument when a patient has experienced symptomatic hypoglycemia on glargine or detemir.

Medicaid prior authorization for Tresiba in Louisiana requires the prescriber to submit documented A1C values, hypoglycemia episode logs, and records of at least two failed basal insulin trials. The process takes 3 to 15 business days. If denied, the patient may appeal through the Louisiana Department of Health Bureau of Health Services Financing within 90 days of the denial notice [4].

Dual-eligible beneficiaries (Medicare Part D plus Medicaid) follow the Part D formulary of their specific plan, not the Louisiana Medicaid PDL. Several CMS-contracted Part D plans available in Louisiana do include Tresiba on Tier 3, putting the copay between $47 and $95 per month after the deductible.

Is Compounded Insulin Degludec Legal in Louisiana?

Compounded insulin degludec is legal in Louisiana through a state-licensed 503A compounding pharmacy, provided the compounding is done for an individual patient with a valid prescription. No 503B outsourcing facility currently holds FDA approval to compound insulin degludec for office stock or resale, so the 503A route is the only legal pathway for patient-specific compounding in the state [6].

The FDA distinguishes 503A pharmacies (patient-specific, licensed by state boards) from 503B outsourcing facilities (FDA-registered, bulk production). Louisiana's Board of Pharmacy enforces 503A standards under Louisiana Revised Statutes Title 37, Chapter 14. Compounded insulin preparations are not FDA-approved, meaning they carry no manufacturer quality guarantee, no validated stability data beyond what the compounding pharmacy establishes internally, and no FDA-reviewed bioequivalence data against branded Tresiba [6].

Some telehealth platforms that operate in Louisiana pair their prescriptions with partner 503A pharmacies and offer compounded long-acting insulin analogs at dramatically reduced cost, sometimes as low as $0 per month under promotional programs. Patients should ask the compounding pharmacy for a certificate of analysis (COA) confirming potency and sterility before accepting the first fill.

The Endocrine Society's clinical practice guidelines on insulin therapy note that formulation differences between compounded and branded insulins can produce clinically meaningful differences in onset and duration [7]. Patients switching from branded Tresiba to a compounded preparation should monitor blood glucose more frequently for at least two weeks.

Which Private Insurance Plans Cover Tresiba in Louisiana?

Coverage depends on the specific plan and plan year. Tresiba is not guaranteed on every commercial formulary in Louisiana. As of 2025 plan filings, BlueCross BlueShield of Louisiana covers insulin degludec on its commercial Tier 3 formulary with a $50 to $75 copay per 30-day supply after the deductible. Humana, UnitedHealthcare, and Aetna each list Tresiba on at least one Louisiana exchange or employer plan, typically at Tier 3 [8].

Patients can verify formulary status by entering Tresiba's NDC (0169-3686-12 for the 100 units/mL FlexTouch, 3 mL, 5-pack) into their insurer's online drug lookup tool. The Novo Nordisk savings card reduces out-of-pocket to $99 per month for commercially insured patients who use it at participating pharmacies, provided their plan does not explicitly prohibit manufacturer copay assistance (some high-deductible employer plans do prohibit it under their benefit structure) [3].

What Savings Programs Are Available for Tresiba in Louisiana?

Several specific programs reduce Tresiba costs for Louisiana residents. Each has different eligibility rules.

Novo Nordisk My$99Insulin Program. This program caps the out-of-pocket cost at $99 per 30-day supply for commercially insured patients regardless of the number of pens needed. Income limits do not apply. Enrollment is at insulinhelp.novo-nordisk.us [3].

Novo Nordisk Patient Assistance Program (PAP). Uninsured or underinsured patients with household income at or below 400 percent of the federal poverty level may qualify for Tresiba at no cost through the PAP. The application requires proof of income and a prescriber signature [3].

GoodRx and Mark Cuban Cost Plus Drugs. GoodRx negotiates pharmacy-level discounts that bring the cash price of Tresiba to roughly $35 per month at many Louisiana locations. Cost Plus Drugs does not currently list branded Tresiba but does list some basal insulin alternatives [9].

340B Program. Louisiana Federally Qualified Health Centers (FQHCs) and certain safety-net hospitals participate in the 340B drug pricing program, which allows them to purchase Tresiba at a significantly reduced acquisition cost and pass savings to eligible patients. Patients must be established at a 340B-covered entity and meet the site's sliding-fee schedule criteria [10].

Louisiana Rx Connect. The state's low-income prescription assistance program, Louisiana Rx, can help patients manage manufacturer PAP applications. It does not directly subsidize Tresiba but connects patients with program enrollment support [4].

The HealthRX clinical team uses a five-step access pathway for Louisiana patients who cannot afford branded Tresiba at list price. Step 1: apply for the Novo Nordisk PAP or My$99Insulin card. Step 2: request a Louisiana Medicaid prior authorization if enrolled in Medicaid, citing ADA 2024 hypoglycemia-risk language. Step 3: if Medicaid denies, evaluate 503A compounded long-acting insulin through a licensed Louisiana compounding pharmacy with a COA. Step 4: explore 340B-eligible clinics in the patient's parish. Step 5: reassess with the prescriber whether a preferred alternative (glargine U-300 or detemir) meets clinical goals, using DEVOTE-equivalent cardiovascular safety data as the benchmark.

How Does Tresiba Perform Clinically? Key Trial Data

Tresiba's formulary position matters less if the clinical evidence doesn't differentiate it. The DEVOTE trial (N=7,637 patients with type 2 diabetes and high cardiovascular risk, 2-year follow-up) compared insulin degludec to insulin glargine U-100 and found a 40% lower rate of severe nocturnal hypoglycemia with degludec (incidence rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001) while demonstrating non-inferior cardiovascular outcomes [2]. That hypoglycemia advantage is the primary clinical argument for preferring Tresiba over glargine in patients with hypoglycemia unawareness or prior severe episodes.

The SWITCH 1 trial (N=501, type 1 diabetes) showed a statistically significant reduction in overall symptomatic hypoglycemia rates with degludec compared to glargine U-100 during the maintenance period (rate ratio 0.89, P<0.05) [11]. SWITCH 2 (N=721, type 2 diabetes) replicated similar findings, with a 30% lower rate of overall symptomatic hypoglycemia during the maintenance period (rate ratio 0.70, P<0.001) [11].

A 2019 systematic review and meta-analysis published in Diabetes Care (N=17 trials, 9,414 participants) found that insulin degludec reduced the rate of nocturnal hypoglycemia by 25% compared to insulin glargine across pooled studies [12]. Glycemic control, measured by HbA1c change from baseline, was equivalent between the two agents.

These trial data matter for Louisiana Medicaid prior authorization submissions. A prescriber citing a documented nocturnal hypoglycemia episode on glargine, combined with DEVOTE's 40% nocturnal hypoglycemia reduction rate, presents a stronger medical necessity argument than one citing general preference [2].

Can a Louisiana Patient Get Tresiba via Telehealth?

Yes. Louisiana permits telehealth prescribing of Schedule V and non-scheduled medications, and insulin degludec is not a controlled substance, so it faces no telehealth prescribing barriers under state law. The Louisiana Board of Medical Examiners requires that a valid prescriber-patient relationship exist before any prescription is issued, which telehealth platforms satisfy through synchronous audio-video encounters [13].

A Louisiana telehealth prescriber can send a Tresiba prescription to any state-licensed pharmacy, including mail-order pharmacies registered in Louisiana. The prescription must include the patient's name, date of birth, the drug name and strength, the quantity, dosing instructions, and the prescriber's DEA number (even for non-controlled medications, most Louisiana pharmacies require it for validation).

Telehealth prescribers can also send a prescription to a licensed Louisiana 503A compounding pharmacy for a patient-specific compounded insulin preparation if branded Tresiba is cost-prohibitive. The compounding pharmacy must be licensed by the Louisiana Board of Pharmacy and in good standing [6].

Tresiba Dosing and Administration: What Louisiana Patients Should Know

Insulin degludec is dosed once daily at any time of day, with the flexibility to shift the injection time by up to 8 hours without loss of glycemic control, as confirmed in flexible dosing sub-studies of the BEGIN trial program [14]. The starting dose for type 2 diabetes naive to insulin is typically 10 units subcutaneously once daily, titrated by 2 units every 3 days to reach a fasting glucose target of 80 to 130 mg/dL per ADA 2024 Standards of Care [5].

For type 1 diabetes, degludec is used as the basal component of a basal-bolus regimen. The FDA-approved label specifies a starting dose of approximately one-third of the total daily insulin requirement for type 1 patients, with rapid-acting insulin covering the remaining two-thirds at mealtimes [1].

Renal impairment does not require a dose adjustment, but patients with creatinine clearance below 30 mL/min may experience reduced insulin clearance and should monitor glucose more closely. Hepatic impairment has a similar effect. The full prescribing information is available on the FDA accessdata portal [1].

Storage before first use: refrigerator at 36 to 46 degrees Fahrenheit. After first use, Tresiba FlexTouch pens can be stored at room temperature (below 86 degrees Fahrenheit) for up to 56 days. In Louisiana's hot summers, patients should avoid leaving pens in a car or direct sunlight, as temperatures regularly exceed 100 degrees Fahrenheit in July and August, which degrades insulin potency [1].

Comparing Tresiba to Other Basal Insulins Available in Louisiana

Louisiana Medicaid's preferred alternatives to Tresiba are insulin glargine (Lantus, Basaglar, Toujeo, and biosimilars including Semglee and Rezvoglar) and insulin detemir (Levemir). Each has a different pharmacokinetic profile, cost structure, and hypoglycemia risk pattern.

Insulin glargine U-100 (Lantus): list price approximately $280/month, preferred on Louisiana Medicaid, 24-hour duration with a small peak around 4 to 8 hours. Semglee (glargine biosimilar, FDA-interchangeable) has a list price near $148/month and is covered on most Louisiana Medicaid and Part D formularies [15].

Insulin detemir (Levemir): list price approximately $315/month, 12 to 24-hour duration, often dosed twice daily, preferred on Louisiana Medicaid.

Insulin glargine U-300 (Toujeo): list price approximately $330/month, 36-hour duration, lower hypoglycemia risk than U-100 glargine, covered on some Louisiana Medicaid prior authorizations and most commercial plans at Tier 3.

For patients whose primary concern is cost, Semglee at $35 to $50/month cash-pay is the most affordable FDA-interchangeable basal insulin alternative in Louisiana. For patients with documented hypoglycemia risk, DEVOTE data support the clinical case for Tresiba despite its higher cost [2].

How to Switch to Tresiba from Another Basal Insulin in Louisiana

Patients switching from once-daily glargine or detemir to insulin degludec use a unit-to-unit conversion on a once-daily basis. Patients switching from twice-daily detemir should use the total daily dose of detemir, then give 80% of that amount as the starting degludec dose once daily to reduce hypoglycemia risk during the transition. These conversion ratios appear in both the FDA label and the ADA 2024 Standards of Care [1][5].

The first 3 to 5 days after switching are the highest-risk period for hypoglycemia, because degludec's ultra-long half-life means it accumulates over 3 to 4 days before reaching steady state. Louisiana patients switching via a telehealth platform should schedule a follow-up glucose review at day 7 and day 14 post-switch.

What Louisiana Patients Should Tell Their Prescriber

The strongest position for a Louisiana patient seeking Tresiba coverage or cost assistance involves four pieces of documentation: a current A1C, a log of hypoglycemia episodes (especially nocturnal ones) on the current basal insulin, records of the current and prior basal insulin trials, and a completed Novo Nordisk PAP or savings card application. Patients with a prior severe hypoglycemia episode (requiring third-party assistance) should document that episode specifically. That history, combined with DEVOTE's confirmed 40% nocturnal hypoglycemia reduction, gives the prescriber a defensible medical necessity argument for both Medicaid prior authorization and commercial plan step-therapy appeals [2][4].